Navigation Links
New study finds that PROMETAT, a controversial methamphetamine treatment program, is ineffective
Date:11/14/2011

A recent study has found that PROMETAT, a popular but controversial treatment for methamphetamine addiction, is no more effective than placebo in reducing methamphetamine use, keeping users in treatment, or reducing cravings for methamphetamine. The study was funded by Hythiam, the company that owns the PROMETAT protocol, and is published online today in the scientific journal Addiction.

Methamphetamine, also known as meth, crystal meth, or ice, is the second most abused illicit drug in the world (cannabis is first), with 15-16 million regular users. The United States saw a rapid growth in methamphetamine addiction in the early 2000s. It was during that epidemic that PROMETAT burst onto the public scene through an aggressive marketing campaign.

Since its introduction, the PROMETAT protocol has been widely used in specialized private clinics in the U.S. as a treatment for methamphetamine addiction without going through the normal drug approval process. Normally, introducing a new medication requires approval by the U.S. Food and Drug Administration, including tests of product safety and a clinical trial to make sure the treatment produces the predicted effects. A loophole in this regulatory system allows a combination of previously approved medications to be marketed without review, whether or not the individual medications were originally approved as a treatment for the condition the new protocol targets. The manufacturer of PROMETAT, Hythiam, was therefore able to market and sell the new protocol with no federal review or clinical trial evidence.

Private patients reportedly pay $12,000 to $15,000 for one month of treatment.

Hythiam used some of its profits to fund the clinical trials long called for by the scientific community, including this one, designed and led by Dr. Walter Ling, a respected U.S. scientist and expert on methamphetamine addiction. Ling and his fellow researchers found that the group of participants given the PROMETAT treatment did not have better outcomes than those given placebo in terms of reducing methamphetamine use, retention in treatment, or reducing methamphetamine cravings.


'/>"/>

Contact: Jean O'Reilly
jean@addictionjournal.org
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Drinking Risky for Women With Family History of Breast Cancer: Study
2. Mayo Clinic study confirms smoke-free workplaces reduce heart attacks
3. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study
4. Sugar-Sweetened Drinks May Pose Heart Risks to Women, Study Suggests
5. Stem cell study helps clarify the best time for therapy to aid heart attack survivors
6. Jefferson researchers study outcomes of carotid artery stenting following prior carotid procedure
7. NIH-funded twin study finds occupational chemical exposure may be linked to Parkinsons risk
8. Study Suggests Exercise May Help Memory of Fibromyalgia Patients
9. Regular Teeth Cleanings Could Cut Heart Attack Risk: Study
10. Abused Girls at Greater Risk for Heart Disease as Adults: Study
11. Intensive Control of Type 1 Diabetes Helps Kidneys: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... ... Controlling and maintaining the home’s water heater just got infinitely easier, more ... Controller , a first-of-its-kind system that enables remote and convenient control of a water ... for HVAC systems, Aquanta gives users a much more efficient, versatile way to use ...
(Date:5/24/2016)... Forest Lake, Minnesota (PRWEB) , ... May 24, ... ... his 13th mission trip to the Dominican Republic on September 21, 2016. Dr. ... Biology from Northwestern, serves with ChiroMission, a not-for-profit organization promoting health and wellness ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... , Out patient Services To Begin In June , Aloria Health, specializing in ... announce the opening of Aloria Milwaukee, its first treatment facility for outpatient, day ...
(Date:5/24/2016)... ... 2016 , ... "ProText Layouts Vol. 3 is a plugin that will keep ... Studios. , ProText Layouts Vol. 3 is a set of 30 self-animating kinetic text ... Layouts, video editors can create an lively typography video with incredible ease. Utilize intuitive ...
(Date:5/24/2016)... ... May 24, 2016 , ... The old expression “a ... problem. A common injury that’s often misunderstood, whiplash should be swiftly diagnosed and treated ... orthopedic spine surgeon at Atlantic Spine Center . , So named because ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 2016 The global  reprocessed medical ... by 2022, according to a new study by Grand ... coupled with the lack of centralized support for waste ... the demand for reprocessed medical devices market. Additionally, the ... that of the original device is the high impact ...
(Date:5/22/2016)... May 23, 2016 DS ... anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive ... non-alcoholic steatohepatitis (NASH) patients. Recent DS ... in lung tissue and has bronchodilatory, anti-inflammatory and ... administration. The Company will publish further detail on ...
(Date:5/20/2016)... 20, 2016 The Biotech arena ... that the industry is not far from recovering. There ... featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ... ATHX ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... ). Sign up for your free trading alerts on ...
Breaking Medicine Technology: